<DOC>
	<DOC>NCT01167062</DOC>
	<brief_summary>This is a randomized double blind placebo-controlled study that will assess the efficacy of Tamsulosin oral-controlled absorption system (OCAS) 0.4 mg in the conjunctive medical treatment of distal ureteral stones with a size of 4-10 mm compared to placebo in control group.</brief_summary>
	<brief_title>Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones</brief_title>
	<detailed_description>- patient will be randomized to receive placebo or Tamsulosin OCAS 0.4 mg 1 tablet OD for a maximum of 28 days or until the ureteral stone is passed and sodium diclofenac 50 mg twice a day, for 10 days. - All patients will receive 75 mg sodium diclofenac via intramuscular on demand</detailed_description>
	<mesh_term>Calculi</mesh_term>
	<mesh_term>Ureteral Calculi</mesh_term>
	<mesh_term>Ureterolithiasis</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Male or female patient aged =&gt; 18 years. Patients who have distal ureteral stones with a size of 410 mm Written informed consent has been obtained. Patients with history of ureteral surgery Patients with urinary tract infection Patient with diabetes and peptic ulcer Patient with renal dysfunction (elevated of serum creatinine level) Patients with severe hydronephrosis Patients with history of passing stones Pregnancy Patients who desire to withdraw from the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>